Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Hong, Tae Hee; Bang, Yeonghak; Joe, CheolYong; Hwang, Soohyun; Lee, Boram; Lee, Naeun; Park, Sehhoon; Jung, Hyun Ae; Sun, Jong‐Mu; Ahn, Jin Seok; Ahn, Myung‐Ju; Choi, Yoon-La; Lee, Se‐Hoon

doi:10.1016/j.jtho.2023.03.024

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of molecular and genomic profiling provides reliable data for prognostication and tailoring the most appropriate targeted therapies. In particular, next-generation sequencing (NGS) has a pivotal role in the management of metastatic non-small cell lung cancer 25 . However, there are solid barriers to the widespread adoption of those tests, especially for resectable diseases 2 , 25 .…”

Section: Discussionmentioning

confidence: 99%

“…In particular, next-generation sequencing (NGS) has a pivotal role in the management of metastatic non-small cell lung cancer 25 . However, there are solid barriers to the widespread adoption of those tests, especially for resectable diseases 2 , 25 . The identification of reliable, fast, and cheap tools for assessing patients' prognosis is of paramount importance for LC, as well as for other solid tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Routine perioperative blood tests predict survival of resectable lung cancer

Morelli,

Cantarutti,

Valsecchi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

There is growing evidence that inflammatory, immunologic, and metabolic status is associated with cancer patients survival. Here, we built a simple algorithm to predict lung cancer outcome. Perioperative routine blood tests (RBT) of a cohort of patients with resectable primary lung cancer (LC) were analysed. Inflammatory, immunologic, and metabolic profiles were used to create a single algorithm (RBT index) predicting LC survival. A concurrent cohort of patients with resectable lung metastases (LM) was used to validate the RBT index. Charts of 2088 consecutive LC and 1129 LM patients undergoing lung resection were evaluated. Among RBT parameters, C-reactive protein (CRP), lymphocytes, neutrophils, hemoglobin, albumin and glycemia independently correlated with survival, and were used to build the RBT index. Patients with a high RBT index had a higher 5-year mortality than low RBT patients (adjusted HR 1.93, 95% CI 1.62–2.31). High RBT patients also showed a fourfold higher risk of 30-day postoperative mortality (2.3% vs. 0.5%, p 0.0019). The LM analysis validated the results of the LC cohort. We developed a simple and easily available multifunctional tool predicting short-term and long-term survival of curatively resected LC and LM. Prospective external validation of RBT index is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Routine perioperative blood tests predict survival of resectable lung cancer

Morelli,

Cantarutti,

Valsecchi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…4 ). Firstly, exclude patients with specific mutations, such as JAK1/2 mutations or PD-L1 copy number loss, which may block the effect of immunotherapy [ 122 , 123 ]. Secondly, select patients who are likely to benefit from immunotherapy, such as those with a high-level expression of PD-L1 in certain types of cancers or having a high relative abundance of specific favorable bacteria.…”

Section: Further Directionsmentioning

confidence: 99%

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Zhang,

Liu,

Xia

2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients’ response to immunotherapy. Several characteristics of the gut microbiome, such as community structures, taxonomic compositions, and molecular functions, have been identified as crucial biomarkers for predicting immunotherapy response and immune-related adverse events (irAEs). Unlike other -omics, the gut microbiome can serve as not only biomarkers but also potential targets for enhancing the efficacy of immunotherapy. Approaches for modulating the gut microbiome include probiotics/prebiotics supplementation, dietary interventions, fecal microbiota transplantation (FMT), and antibiotic administration. This review primarily focuses on elucidating the potential role of the gut microbiome in predicting the response to cancer immunotherapy and improving its efficacy. Notably, we explore reasons behind inconsistent findings observed in different studies, and highlight the underlying benefits of antibiotics in liver cancer immunotherapy.

show abstract

Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond

Inamura

2023

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Cited by 3 publications

References 25 publications

Routine perioperative blood tests predict survival of resectable lung cancer

Routine perioperative blood tests predict survival of resectable lung cancer

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond

Contact Info

Product

Resources

About